Giuseppe Curigliano: With T-DXd for HR-Positive Metastatic Breast Cancer

Giuseppe Curigliano shared an article on X:

“DESTINY-Breast06 Shows Significant PFS Improvement With T-DXd for HR-Positive Metastatic Breast Cancer. How Do These Results Impact Practice for All Patients?”

Title: DESTINY-Breast06 Shows Significant PFS Improvement With T-DXd for HR-Positive Metastatic Breast Cancer. How Do These Results Impact Practice for All Patients?

Authors: Giuseppe Curigliano and Aditya Bardia.

Source: Giuseppe Curigliano/X

Giuseppe Curigliano, MD, PhD, is the Director of  the Early Drug Development Division and co-chairs the Experimental Therapeutics Program at the European Institute of Oncology. He is a member of the Department of Oncology and Hemato-Oncology’s steering committee at the University of Milan and serves on the Italian National Health Council, advising the Ministry of Health on cancer policy issues. He is the Editor-in-Chief of ESMO Open, the European Society for Medical Oncology’s open-access journal.